Big thanks to @BillGates for supporting the development of blood biomarkers for Alzheimer's disease, which holds great promise to both revolutionize the diagnostic and prognostic work-up of the disease globally and speed up the development of new effective therapies.

🚨New paper alert! This study led by @SEMastenbroek aims to make detection of α-synuclein pathology in the brain more time- and cost-effective. Out now in Nature Communications! 🔗 Full article: https://t.co/0tLceNyO5M A thread🧵👇

Tau PET positivity in individuals (42 cohorts worldwide, N = 12,048) with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex @RikOssenkoppele, @OskarHansson9, @AlzheimerAms, @biofinder_study https://t.co/8IROVZ15yT

Who peer-reviews the paper when everyone in the field is an author? @RikOssenkoppele @OskarHansson9 & collaborators conduct a multicenter analysis of 42 cohorts worldwide (N = 12K) exploring Tau PET positivity in individuals with & without cog. impairment https://t.co/rzGbRlCjmb

I think these findings will be crucial when designing trials aimed at targeting Alzheimer's disease in Down Syndrome. These findings are timely, since human trials evaluating the effects of e.g. amyloid targeted immunotherapies and APP lowering therapies are underway.

Most individuals with Down Syndrome develop Alzheimer's disease causing subsequent cognitive decline and dementia. We show that plasma p-tau217 accurately predict decline in global cognition, progression to dementia, and increased tau burden.

Can we accurately predict cognitive decline in people with Down Syndrome using simple blood tests? Here is a paper recently published in Lancet Neurology showing that especially plasma p-tau217 is a promising candidate. https://t.co/tns3B4LkgU

Individuals with more severe clinical Alzheimer disease symptoms than their biological stage often have additional pathologies. https://t.co/EXSnFgSTOR

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇 https://t.co/hUKOOQ5glq

Immunoassay choice for #pTau217 is important! In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives. https://t.co/47f2rRYXmH @biofinder_study @OskarHansson9

Fantastic work by @teanijarv et al! Not a bad first paper to have in the thesis! 🤩

Plasma eMTBR-tau243 is a specific #biomarker of #tau tangles in #Alzheimer’s disease and enables the detecting and tracking of Alzheimer’s clinical impairment. #NeurodegenerativeDiseases #AlzheimersAwareness #Biomarkers https://t.co/YhRUGwXjqC

p-Tau217 is a breakthrough blood test that can accurately predict and may help prevent Alzheimer's disease. https://t.co/mq02BanLe2 Here's the rundown on it. Free, open-access.

We're entering a new era of #Alzheimers blood testing—fully automated platforms now deliver fast, accurate #pTau217 results for use in primary & secondary care. Proud to share senior authorship and proud of this multi-centre European collaboration. 🔗

New manuscript alert! Can blood-based biomarkers measured on a fully automated platform accurately identify Alzheimer’s disease (AD) pathology?🩸 Our new multi-cohort study has now been published in @NatureMedicine: https://t.co/lfHLuk86Gr. A thread🧵

In a head-to-head comparison, plasma p-tau217 and tau-PET imaging equally predict which healthy people will develop mild cognitive impairment. Still, using both could streamline selection for clinical trials. @lunduniversity @amsterdamumc

Great new study out in @NatureMedicine identifies #Plasma eMTBR-tau243 as a specific #biomarker of #tau tangles in #Alzheimers disease, enabling the detecting and tracking of Alzheimer’s clinical impairment. #ADPD2025 https://t.co/C3uLXxYjeR

First panel of the DxA Day focuses on the current diagnostic landscape for Alzheimer’s - from development to implementation, featuring an expert panel les by @NicholasAshton of @BannerHealth. CC @OskarHansson9, @C2NDiagnostics, @washumedicine, @BCILifeSciences and @biogen

https://t.co/ZyYpOZadpt

New Alzheimer blood biomarker! Plasma eMTBR-tau243 correlates strongly with tau tangle pathology, brain atrophy and cognitive decline. I believe it will complement p-tau217 in clinical practice and in many trials. https://t.co/Dz4YY8sJLh

Finally, I would like to thank our incredible team including @ccrugom, @OskarHansson9, @nfranzme, David Bennet, Henrik Zetterberg, Deniz Urey, @karlssonlinda1, Zeyu Zhu, and the research participants who have made this work possible! Full study 🔗: https://t.co/yg8lmRXuTN 12/12